Home › Funds › ARMISTICE CAPITAL, LLC › RIGL

ARMISTICE CAPITAL, LLC position in RIGL

RIGEL PHARMACEUTICALS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 1,672,000 shares of RIGL (RIGEL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$65.4M, representing 0.86% of its reported portfolio and ranking #13 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed RIGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.67M sh
Reported value held$65.41M
Portfolio Weight0.86%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's RIGL position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in RIGL in Q3 2023 at 17,136,000 shares (US$18.5M). The position peaked in Q2 2026 at 1,672,000 shares, worth US$65.4M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,672,000 shares valued at US$65.4M — an increase of 392,000 shares quarter over quarter.. Notable position changes include a 89% trim in Q2 2024 (shares rose 97% over the following quarter), a 55% trim in Q3 2025 (shares rose 51% over the following quarter), a 53% increase in Q1 2026 (shares rose 45% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 17.14M $18.51M New
Q4 2023 17.10M $24.80M Hold
Q1 2024 15.36M $22.73M Reduce
Q2 2024 1.62M $13.35M Reduce
Q3 2024 1.54M $24.85M Reduce
Q4 2024 1.15M $19.38M Reduce
Q1 2025 1.52M $27.27M Add
Q2 2025 1.60M $29.97M Add
Q3 2025 724.00K $20.51M Reduce
Q4 2025 836.00K $35.81M Add
Q1 2026 1.28M $34.61M Add
Q2 2026 1.67M $65.41M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RIGL and 13F data

RIGL (RIGEL PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in RIGL — the largest reported positions include Soleus Capital Management, L.P. (US$72.1M), CM Management, LLC (US$9.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RIGL

All RIGL fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held RIGL?

ARMISTICE CAPITAL, LLC has disclosed RIGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in RIGL?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 1.67M shares of RIGL (RIGEL PHARMACEUTICALS INC), valued at $65.41M, representing 0.86% of its reported portfolio and ranking #13.

Has ARMISTICE CAPITAL, LLC been buying or selling RIGL?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC increased its position in RIGL. The position peaked in Q2 2026 at 1.67M shares.

Which other funds hold RIGL?

Other major institutional holders of RIGL include Soleus Capital Management, L.P., CM Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.